Q2 2025 Mckesson Corp Earnings Call Transcript
Key Points
- McKesson Corp (MCK) reported record quarterly revenue of $93.7 billion, with a 7% increase in adjusted operating profit.
- The company raised its fiscal 2025 guidance for adjusted earnings per diluted share, reflecting confidence in its business outlook.
- Strong performance was noted in the US pharmaceutical segment, driven by increased prescription volumes and the onboarding of a new strategic partner.
- McKesson Corp (MCK) continues to expand its oncology platform, with significant growth in the US Oncology Network and strategic acquisitions.
- The company is making strategic investments in technology and modernization initiatives, expected to generate $250 million in benefits over the next five years.
- The Medical-Surgical Solutions segment experienced lower volumes in the primary care channel, impacting operating profit.
- There is variability and challenges in the Prescription Technology Solutions segment, with product launch delays and slower manufacturer program ramps.
- The company recorded a GAAP-only charge of $643 million related to the divestiture of its Canada-based Rexall and Well.ca businesses.
- McKesson Corp (MCK) faces ongoing challenges in managing costs and operational efficiencies amid market normalization post-COVID.
- The company anticipates continued variability in GLP-1 medication revenues, which could impact future financial performance.
Ladies and gentlemen, welcome to McKesson's second quarter fiscal 2024 earnings conference call. Please be advised that today's conference is being recorded.
At this time, I'd like to turn the conference over to Rachel Rodriguez, Vice President of Investor Relations. Please go ahead, ma'am.
Thank you, operator. Good afternoon, and welcome, everyone to McKesson's second quarter fiscal 2025 earnings call. Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. Brian will lead off, followed by Britt, and then we will move to a question-and-answer session.
Today's discussions will include forward-looking statements such as forecast about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com.
And to the Risk Factors section of our most recent annual report and other SEC filings for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
